Sugi Predict

Sugi Predict / Compounds / SCHEMBL2394623

SCHEMBL2394623

SCHEMBL2394623

O=C(Nc1ccc(C(=O)O)c(F)c1)c1cc2c3c(c1)CCCCC3CCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARA P10276 1/20 0.48
▸ RARB P10826 1/20 0.48
▸ RARG P13631 1/20 0.48
▸ CPT1A P50416 6/20 0.46
▸ CPT1B Q92523 6/20 0.46
▸ NPC1 O15118 6/20 0.45
▸ RAB9A P51151 6/20 0.45
▸ NFKB1 P19838 4/20 0.44
▸ NFKB2 Q00653 4/20 0.44
▸ RELA Q04206 4/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ TP53 P04637 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ S1PR1 P21453 1/20 0.43
▸ CPT2 P23786 5/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LY96 Q9Y6Y9 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398403 0.97 RARA (0.49) RARARARBRARGCPT1ACPT1B
SCHEMBL2395673 0.88 NPC1 (0.43) RARARARBRARGCPT1ACPT1B
SCHEMBL2393108 0.87 KMT2A (0.59) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL2392613 0.86 CPT2 (0.45) CPT1ACPT1BNPC1RAB9ANFKB1
SCHEMBL2394416 0.85 RARA (0.46) RARARARBRARGNPC1RAB9A
SCHEMBL2393104 0.84 NPC1 (0.44) RARARARBRARGCPT1ACPT1B
SCHEMBL2397423 0.84 KMT2A (0.60) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL2396333 0.84 MCHR1 (0.46) CPT1ACPT1BNPC1RAB9ANFKB1
SCHEMBL2393053 0.83 MEN1 (0.52) RARARARBRARGNPC1RAB9A
SCHEMBL2395262 0.83 CPT2 (0.46) CPT1ACPT1BNPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11116738-B2 Methods for treating neutropenia using retinoid agonists CHILDREN'S HOSPITAL LOS ANGELES (US) 2021-09-14 — — US disclosed
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 — — EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 — — US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 — — US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 — — US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 — — US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 — — US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 — — US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG RARA 8/4885RARB 12/4885RARG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.